GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a ...

Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

Corona Remedies acquires cardiology and women's healthcare brands from Bayer, entering new segments ahead of IPO.

The motor neuron disease treatment market is witnessing substantial growth, primarily fueled by the rising incidence of conditions like Amyotrophic L ...